



(11) **EP 2 248 895 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(51) Int Cl.:  
**C12N 15/113** <sup>(2010.01)</sup>      **A61K 31/7125** <sup>(2006.01)</sup>  
**A61K 31/04** <sup>(2006.01)</sup>      **A61K 31/166** <sup>(2006.01)</sup>  
**A61K 31/52** <sup>(2006.01)</sup>      **A61K 31/7048** <sup>(2006.01)</sup>  
**A61K 38/18** <sup>(2006.01)</sup>      **A61P 35/00** <sup>(2006.01)</sup>  
**C07K 14/495** <sup>(2006.01)</sup>

(48) Corrigendum issued on:  
**21.09.2016 Bulletin 2016/38**

(45) Date of publication and mention  
of the grant of the patent:  
**06.07.2016 Bulletin 2016/27**

(21) Application number: **10009016.6**

(22) Date of filing: **20.12.2004**

---

(54) **Combination therapy associating a TGF-beta antagonist with a chemotherapeutic agent**  
Kombinations-therapie die ein TGF-beta Antagonisten mit einem Chemotherapeutikum assoziiert  
Thérapie combinatoire associant un antagoniste du TGF-beta avec un agent chimiothérapeutique

---

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR**

(74) Representative: **V.O.**  
**P.O. Box 87930**  
**2508 DH Den Haag (NL)**

(30) Priority: **19.12.2003 EP 03029367**  
**05.02.2004 US 541771 P**

(56) References cited:  
**WO-A-94/25588      WO-A-99/63975**  
**WO-A-2004/005552**

(43) Date of publication of application:  
**10.11.2010 Bulletin 2010/45**

(60) Divisional application:  
**16177969.9**

(62) Document number(s) of the earlier application(s) in  
accordance with Art. 76 EPC:  
**04804940.7 / 1 694 840**

(73) Proprietor: **Autotelic LLC**  
**City of Industry, CA 91748 (US)**

- **ARTEAGA C L ET AL: "REVERSAL OF TAMOXIFEN RESISTANCE OF HUMAN BREAST CARCINOMAS IN VIVO BY NEUTRALIZING ANTIBODIES TO TRANSFORMING GROWTH FACTOR-BETA", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 91, no. 1, 6 January 1999 (1999-01-06), pages 46-53, XP000940473, ISSN: 0027-8874**
- **WOJTOWICZ-PRAGA SLAWOMIR: "Reversal of tumor-induced immunosuppression by TGF-beta inhibitors.", INVESTIGATIONAL NEW DRUGS, vol. 21, no. 1, February 2003 (2003-02), pages 21-32, XP008035079, ISSN: 0167-6997**

(72) Inventors:

- **Schlingensiepen, Karl-Hermann**  
**93093 Donaustauf (DE)**
- **Schlingensiepen, Reimar**  
**93051 Regensburg (DE)**

**EP 2 248 895 B8**

---

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

---

- JACHIMCZAK P ET AL: "THE EFFECT OF TRANSFORMING GROWTH FACTOR-BETA 2-SPECIFIC PHOSPHOROTHIIOATE-ANTI-SENSE OLIGODEOXYNUCLEOTIDES IN REVERSING CELLULAR IMMUNOSUPPRESSION IN MALIGNANT GLIOMA", JOURNAL OF NEUROSURGERY, vol. 78, no. 6, 1993, pages 944-951, XP000886109, ISSN: 0022-3085

- YU D ET AL: "HYBRID OLIGONUCLEOTIDES: SYNTHESIS, BIOPHYSICAL PROPERTIES STABILITY STUDIES, AND BIOLOGICAL ACTIVITY", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 4, no. 10, 1996, pages 1685-1692, XP000644792, ISSN: 0968-0896